Moderna

Moderna Inc (NASDAQ: MRN) shares are surging above the $70 level for the first time since late May following sell-side commentary on its coronavirus vaccine program. The Moderna Analyst: Jefferies analyst Michael Yee initiated coverage of Moderna with a Buy rating and $90 price target. The Moderna Thesis: There is good probability the vaccine will work…

July 13, 2020 11:11 am ET Order Reprints Print Article Text size Maddie Meyer/Getty Images Shares of Moderna are up 239% so far this year, and the biotech company, which has no approved drugs, has a market capitalization of more than $24 billion. But in a note out Monday morning, Jefferies analyst Michael Yee writes…

The two sides are apparently arguing over several issues, including protocols and information sharing. Gearing up for a phase 3 clinical trial of its coronavirus vaccine candidate, mRNA-1273, Moderna (NASDAQ:MRNA) is apparently butting heads with federal government officials. Tensions between the company and the officials have delayed the start of the trial. This is according…

FILE PHOTO: The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the NYSE in New YorkGENEVA (Reuters) - AstraZeneca's experimental COVID-19 vaccine is probably the world's leading candidate and most advanced in terms of development, the World Health Organization's (WHO) chief scientist said on Friday.The British drugmaker has…

Moderna said Thursday that starting in 2021, it could manufacture "possibly up to 1 billion doses per year" of its experimental coronavirus vaccine with the help of a contract manufacturer.Yes, but: 1 billion vaccine doses may sound like a lot, but government and public health leaders would inevitably still have to make hard choices about…